Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04599491
Other study ID # INTELLiSTREAM
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 30, 2020
Est. completion date May 21, 2022

Study information

Verified date July 2022
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background INTELLiVENT-ASV, an automated closed-loop mode of mechanical ventilation, available on Hamilton ventilators for clinical use, uses mainstream end-tidal CO2 (etCO2) monitoring to adjust minute ventilation. However, sensors for mainstream etCO2 monitoring are expensive and fragile. The less expensive and more robust sensors for sidestream etCO2 monitoring could serve as a good alternative to sensors for mainstream etCO2 monitoring. Objective of the study The objective of this randomized noninferiority trial is to determine whether INTELLiVENT- ASV with sidestream capnography is noninferior to INTELLiVENT-ASV with mainstream capnography with regard to the percentage of breaths in a broadly accepted predefined 'optimal' zone of ventilation. Hypothesis The investigators hypothesize that INTELLiVENT-ASV with sidestream capnography is noninferior to INTELLiVENT-ASV with mainstream capnography with respect to the percentage of breaths a patient spends within the 'optimal' zone of ventilation. Study design INTELLiSTREAM is a randomized noninferiority study. Study population The study population consists of consecutive elective cardiac surgery patients who are expected to need at least 2 hours of postoperative ventilation in the ICU of Amsterdam Medical University Centers, location 'AMC'. Intervention Shortly after arrival at the ICU, patients will be randomized to receive either ventilation with INTELLiVENT-ASV with mainstream capnography or sidestream capnography. Primary outcome of the study The primary study endpoint is the percentage of breaths a patient spends inside the 'optimal' zone of ventilation, as defined before (i.e. tidal volume < 10 ml/kg PBW, maximum airway pressure < 30cm H2O, etCO2 between 30-46 mmHg and pulse oximetry between 93-98%). Secondary outcomes The percentage of time spent in other ventilation zones, as defined in the protocol. Time to spontaneous breathing, duration of weaning, loss of etCO2 signal, duration of postoperative ventilation and ventilator parameters as well as results of clinically indicated arterial blood gas analysis. Nature and extent of burden and risks associated with participation, benefit and group relatedness Hamilton ventilators can use mainstream and sidestream etCO2 sensors. INTELLiVENT-ASV is a safe mode of ventilation, also in patients who receive postoperative ventilation. Furthermore, as all patients are sedated as part of standard care during postoperative ventilation, the burden for the patient is minimal


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date May 21, 2022
Est. primary completion date April 21, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Undergoing elective cardiac surgery in the Amsterdam University Medical Centers, location 'AMC' - Planned admission to the ICU for postoperative ventilation - Expected to need postoperative ventilation for at least 2 hours Exclusion Criteria: - Age under 18 years - Patients previously included in the current clinical trial - Patients participation in other interventional clinical trials that could influence ventilator settings and ventilation parameters - Patients with suspected or confirmed pregnancy - Moribund patients

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Sidestream capnography using the 'Respironics LoFlo Sidestream CO2 Module'
Study patients randomized into the 'Sidestream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring using the 'Respironics LoFlo Sidestream CO2 Module'.
Mainstream capnography using the 'Respironics Capnostat 5 Mainstream CO2 sensor'
Study patients randomized into the 'Mainstream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring using the 'Respironics Capnostat 5 Mainstream CO2 sensor'.

Locations

Country Name City State
Netherlands Amsterdam UMC location AMC Amsterdam

Sponsors (1)

Lead Sponsor Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary The percentage (%) of time spent in the 'optimal' zone of ventilation during the first 3 hours of postoperative ventilation using INTELLiVENT-ASV. A breath is considered to be in the 'optimal zone' when the following criteria are met: tidal volume (VT) =8 ml/kg predicted body weight (PBW) and maximum airway pressure (Pmax) = 30 cmH2O and end tidal CO2 (etCO2) = 30-46 mmHg and pulse oximetry saturation (SpO2) = 93-98%.
The ventilation zones are as defined in earlier studies (ClinicalTrials.gov Identifier: NCT03180203)
During the first 3 hours, since admission on the intensive care unit (ICU) with the start of INTELLiVENT-ASV ventilation mode.
Secondary The percentage (%) of time spent in the 'optimal', 'acceptable' and 'critical' zones during the first 3 hours of postoperative ventilation using INTELLiVENT-ASV. An optimal zone as defined under Primary Outcome Measure
An acceptable zone = VT = 8-12 ml/kg PBW with an etCO2 = 25-30 or 45-50 mmHg, a Pmax = 31-36 cmH2O and a SpO2 = 85-93% or >98%.
A critical zone = VT >12 ml/kg PBW or an etCO2 = <25 or =51 mmHg, a Pmax =36 cmH2O or SpO2 <85%.
During the first 3 hours, since admission on the ICU with the start of the INTELLiVENT-ASV ventilation mode.
Secondary Time to spontaneous breathing Time to spontaneous breathing is defined as the time from start of ventilation at the ICU until five or more consecutive spontaneous breaths. Time from start of ventilation at the ICU until five or more consecutive spontaneous breaths, assessed up to 30 days.
Secondary Duration of weaning Duration of weaning is defined as time from cessation of sedatives and of a rectal temperature > 35.5ÂșC to tracheal extubation. Time from cessation of sedatives and of a rectal temperature > 35.5ºC to tracheal extubation, assessed up to 30 days.
Secondary Duration of postoperative ventilation Duration of postoperative ventilation, defined as time from start of ventilation at the ICU until tracheal extubation Time from start of ventilation at the ICU until tracheal extubation, assessed up to 30 days.
Secondary Proportion of failed extubations Failed extubations are defined as re-intubation within 48 hours after extubation and considering only patients who survived and did not undergo re-sternotomy during this time. Within 48 hours after extubation.
Secondary Development of postoperative pulmonary complications Postoperative pulmonary complications is collapsed composite of pneumonia, defined as a patient receiving antibiotics and meets at least one of the following criteria: new or changed sputum, new or changed lung opacities on chest radiography when clinically indicated, tympanic temperature > 38.3C, white blood cell count 12,000/mm^3, pneumothorax, defined as air in he pleural space with no vascular bed surrounding the visceral pleura on chest radiography or severe atelectasis, defined as lung opacification with a shift of the mediastinum, hilum or hemidiaphragm towards the affected area, and compensatory over-inflation in the adjacent non-atelectatic lung on chest radiography. During first 5 postoperative days days.
Secondary Length of stay in ICU From admission to ICU to ICU discharge of the patient, assessed up to 30 days.
Secondary Readmission to ICU From admission to ICU to hospital discharge of the patient, assessed up to 30 days.
Secondary Mortality in the ICU From admission to ICU to ICU discharge of the patient, assessed up to 30 days.
Secondary Loss of capnography signal Loss of etCO2 monitoring requiring a correction by ICU nurses. During the first 3 hours, since admission on the ICU with the start of INTELLiVENT-ASV ventilation mode.
Secondary Incidence of hypoxemia Hypoxemia is defined as percentage of breath with pulse oximetry saturation <85% but only when SpO2 had a quality index >50%. Time from start of ventilation at the ICU until tracheal extubation, assessed up to 30 days.
Secondary Ventilatory parameters: pressures Positive end expiratory pressure (PEEP), maximum airway pressure (Pmax) and plateau pressure (Pplat) Time from start of ventilation at the ICU until tracheal extubation, assessed up to 30 days.
Secondary Ventilation parameters: volumes Tidal volume (VT) and minute volume (MV) Time from start of ventilation at the ICU until tracheal extubation, assessed up to 30 days.
Secondary Ventilation parameters: respiratory rate Respiratory rate (RR) Time from start of ventilation at the ICU until tracheal extubation, assessed up to 30 days.
Secondary Ventilation parameters: oxygenation Fraction inspired oxygen (FiO2) and pulse oximetry (SpO2) Time from start of ventilation at the ICU until tracheal extubation, assessed up to 30 days.
Secondary Ventilation parameters: capnography End-tidal CO2 (etCO2) Time from start of ventilation at the ICU until tracheal extubation, assessed up to 30 days.
Secondary Clinically indicated arterial blood gas analyses Time from start of ventilation at the ICU until tracheal extubation, assessed up to 30 days.
See also
  Status Clinical Trial Phase
Recruiting NCT05030337 - Optimising Ventilation in Preterms With Closed-loop Oxygen Control N/A
Completed NCT05144607 - Impact of Inspiratory Muscle Pressure Curves on the Ability of Professionals to Identify Patient-ventilator Asynchronies N/A
Recruiting NCT03697785 - Weaning Algorithm for Mechanical VEntilation N/A
Completed NCT05084976 - Parental Perception of COVID-19 Vaccine in Technology Dependent Patients
Active, not recruiting NCT05886387 - a Bayesian Analysis of Three Randomised Clinical Trials of Intraoperative Ventilation
Completed NCT04429399 - Lowering PEEP: Weaning From High PEEP Setting N/A
Completed NCT02249039 - Intravenous Clonidine for Sedation in Infants and Children Who Are Mechanically Ventilated - Dosing Finding Study Phase 1
Recruiting NCT02071524 - Evaluation of the Effects of Fluid Therapy on Respiratory Mechanics N/A
Completed NCT01114022 - Prevention Inhalation of Bacterial by Using Endotracheal Tube Balloon Polyvinyl Chloride or Polyurethane N/A
Completed NCT00893763 - Strategies To Prevent Pneumonia 2 (SToPP2) Phase 2
Terminated NCT05056103 - Automated Secretion Removal in ICU Patients N/A
Active, not recruiting NCT04558476 - Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation Phase 2
Recruiting NCT05295186 - PAV Trial During SBT Trial
Active, not recruiting NCT05370248 - The Effect of 6 ml/kg vs 10 ml/kg Tidal Volume on Diaphragm Dysfunction in Critically Mechanically Ventilated Patient N/A
Completed NCT04589910 - Measuring Thickness of the Normal Diaphragm in Children Via Ultrasound. N/A
Completed NCT04818164 - Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
Completed NCT04193254 - LPP , MP and DP:Relation With Mortality and SOFA in Mechanically Ventilated Patients in ER, Ward and ICU
Completed NCT06332768 - NIV Versus HFO Versus Standard Therapy Immediately After Weaning From Mechanical Ventilation in ARDS Patients N/A
Not yet recruiting NCT03259854 - Non Invasive Mechanical Ventilation VERSUS Oxygen MASK N/A
Not yet recruiting NCT03245684 - Assisted or Controlled Ventilation in Ards (Ascovent) N/A